Proteomics International Laboratories Ltd (PIQLF) Quarterly Activities Report

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics is pleased to provide the following update on its business activities for the three months to 31 March 2025 and subsequent to the period end.

- Launched PromarkerD predictive test for diabetic kidney disease in Australia: Test launched on World Kidney Day to Australian healthcare professionals and paving the way for global commercialisation

- PromarkerD outperforms conventional tests: Landmark results published in international peer reviewed journal, Diagnostics, demonstrate PromarkerD significantly outperforms standard of care tests in identifying the risk of diabetes-related chronic kidney disease (DKD)

- Opened CLIA certified USA Reference Laboratory in California: Launched new laboratory and secured a Clinical Laboratory Improvement Amendment ("CLIA") certificate of registration, enabling Proteomics International to offer clinical laboratory services within the United States

- Australian patent granted for OxiDx technology: Proteomics International's subsidiary OxiDx Pty Ltd granted a new Australian patent for its platform technology to measure oxidative stress

Financial and Corporate Highlights

- Appointment of Tim Luscombe as Company Secretary

- Proteomics International receives strong support for $4.5m placement

*To view the full Quarterly Report, please visit:
https://abnnewswire.net/lnk/67U7I1J4

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Dirk van Dissel 
Investor Relations and Corporate Advisor
Candour Advisory
T: +61 408 326 367 
E: dirk@candouradvisory.com.au

Matthew Wright
Media and Public Relations
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

News Provided by ABN Newswire